Also, left ventricular fractional area change, fractional shortening, stroke volume, and left ventricular mass did not change 6 days after Ad-VEGF-B186R127S and Ad-VEGF-B186 gene transfers as compared to controls which showed impairment of the heart functions (Figures 9B–D) and no cardiac arrhythmias were detected in the study groups (Supplementary Figure S7). This evidence concerns the gene VEGFA and cardiac arrhythmia.